Denied fevers, weight loss, visual or neurologic deficits. Denied sick contacts including anyone with tuberculosis

Size: px

Start display at page:

Download "Denied fevers, weight loss, visual or neurologic deficits. Denied sick contacts including anyone with tuberculosis"

Basil Wilson
7 years ago
Views:

1 Is that contagious?

2 HPI: Previously healthy 16 y/o male on return from a 4 year stay in Nigeria presented with a rash on his face, back and upper and lower extremities that had become more prominent over the past four months The rash was first noted on his lower extremities 12 months earlier and was initially pruritic but the involvement of his upper extremities and face was non-pruritic and painless Seen by physicians in Nigeria 6 months earlier and was given a powder to apply to the rash on his lower extremities which did not improve his symptoms Applying olive oil to the rash on his face with no relief Denied fevers, weight loss, visual or neurologic deficits Denied sick contacts including anyone with tuberculosis

and face was non-pruritic and painless Seen by physicians in Nigeria 6 months earlier and was given a powder to apply to the rash on his lower extremities which did not improve

3 PMH: None Medications: None Immunizations: Up to date Social History: Born in Nigeria and immigrated to the U.S. at age 2 Attending boarding school in Nigeria for the past 4 years. He reported no classmates or teachers with similar dermatologic symptoms. While in Nigeria had had visited a rural village where there was no running water Exposure to goats, cows, and chickens. Denies sexual activity, alcohol, or drug use

He reported no classmates or teachers with similar dermatologic symptoms.

4 PE: T: 36.8 C, BP: 116/67, HR: 67, RR: 18 GEN: Comfortable, pleasant male with obvious lesions on face EXT: 2 + pitting edema was noted up to his knees bilaterally. SKIN: Lichenified skin was noted on both shins. Papules, nodules, and plaques were noted on his face, ears, upper and lower extremities with sparing of the trunk. Some hypopigmented patches were noted on his back. NEURO: There was prominence of the temporal, ulnar and popliteal nerves. Neurologic exam was grossly intact. All sensation was normal including fine touch and proprioception. Remainder of exam was normal

bilaterally. SKIN: Lichenified skin was noted on both shins.

8 Studies: CBC: WBC 6.84 Thou/uL (S-68%, L-22%, M-4%, E-6%) Hgb 12.6 g/dl Hct-37.3% Plt-279 Thou/uL Chemistries and LFTs: Normal UA: Normal Chest x-ray: Normal HIV ELISA: Negative

9 Diagnostic testing Patient underwent a skin biopsy from one of the lesions on his left arm. Stains from the tissue revealed: Skin, H&E Stain, 200X (Courtesy of Douglas Parker, MD)

10 Differential Diagnosis 1) Cutaneous leishmaniasis 2) Cutaneous onchocerciasis (Onchocerca volvulus) 3) Lepromatous leprosy (Hansen s Disease) 4) Mycobacterium marinum 5) Human Immunodeficiency Virus (HIV) type 2 infection 6) Fungal dermatitis 7) Allergic reaction to homeopathic therapy

Disease) 4) Mycobacterium marinum 5) Human Immunodeficiency Virus (HIV)

11 Diagnosis and Follow-up Ziehl-Neelsen staining did not identify acid fast organisms but a modified Fite-Faraco stain demonstrated numerous bacilli within histiocytes consistent with Mycobacterium leprae He was started on dapsone, rifampin and clofazimine Noticeable reduction in size and distribution of lesions after 6 months of therapy Will undergo a skin biopsy after 12 months of therapy to guide duration of therapy. Plans are for a minimum of 24 months of treatment

rifampin and clofazimine Noticeable reduction in size and distribution of lesions after 6 months of therapy Will

12 Leprosy (Hansen s Disease) Disease caused by bacillus Mycobacterium leprae Spectrum of disease manifestations related to cell mediated immune response Highly infectious but low virulence - Believed to be spread by direct contact or nasal droplet - Skin and peripheral nerves most affected organs Incubation period 2-5 Years

Highly infectious but low virulence - Believed to be spread by direct contact or

13 Leprosy: Keys to Diagnosis Diagnosis is Clinical: Hypopigmented or erythematous anesthetic plaque Leonine Facies and madarosis Peripheral Nerve Thickening Decrease in peripheral sensation to fine touch and vibration

Leonine Facies and madarosis Peripheral Nerve

14 Diagnostic Confirmation Skin Biopsy or Scraping: Modified Fite-Faraco Stain Histopathologic appearance varies with type of leprosy Number of organisms Number of histiocytes, plasma cells, and lymphocytes Extent of organism invasion into subepidermal layers Invasion of organism into superficial nerves

Number of histiocytes, plasma cells, and lymphocytes Extent of organism

15 Treatment and Prognosis Multi-drug Therapy: Dapsone Rifampin Clofazimine Need to check for G6PD and TB prior to initiating therapy Recommended length of therapy is minimum of 2 years Goal of therapy is prevention of permanent nerve damage Leprosy is curable

therapy Recommended length of therapy is minimum of 2 years Goal

16 Final Diagnosis Lepromatous Leprosy (Hansen s Disease) caused by Mycobacterium leprae

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.